<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28630863</article-id><article-id pub-id-type="pmc">5467275</article-id><article-id pub-id-type="doi">10.1155/2017/3204504</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chojnacki</surname><given-names>Cezary</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>B&#x00142;o&#x00144;ska</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8766-7868</contrib-id><name><surname>Chojnacki</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University, Lodz, Poland</aff><aff id="I2"><sup>2</sup>Department of Gastroenterology, Medical University, Lodz, Poland</aff><author-notes><corresp id="cor1">*Jan Chojnacki: <email>jan.chojnacki@umed.lodz.pl</email></corresp><fn fn-type="other"><p>Academic Editor: Thomas Minor</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>29</day><month>5</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>3204504</elocation-id><history><date date-type="received"><day>1</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Cezary Chojnacki et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Taking statins can cause increase in the level of aspartate and alanine aminotransferase. The aim of this study was to assess the usefulness of melatonin in counteracting the adverse hepatic events from statins.<italic> Methods</italic>. The research program included 60 patients (aged 47&#x02013;65 years, 41 women and 19 men) with hyperlipidemia taking atorvastatin or rosuvastatin at a dose of 20&#x02013;40&#x02009;mg daily. The patients were randomly allocated in two groups. Group I (<italic>n</italic> = 30) was recommended to take the same statin at a standardized daily dose of 20&#x02009;mg together with melatonin at a dose of 2 &#x000d7; 5&#x02009;mg. Group II (<italic>n</italic> = 30) patients took statin with placebo at the same dose and time of the day. Follow-up laboratory tests (AST, ALT, GGT, and ALP) were evaluated after 2, 4, and 6 months of treatment.<italic> Results</italic>. In Group I the levels of all enzymes decreased after 6 months, particularly AST, 97,2 &#x000b1; 19,1&#x02009;U/L versus 52,8 &#x000b1; 12,3&#x02009;U/L (<italic>p</italic> &#x0003c; 0,001); ALT, 87,4 &#x000b1; 15,6&#x02009;U/L versus 49,8 &#x000b1; 14,5&#x02009;U/L (<italic>p</italic> &#x0003c; 0,001); and GGT, 84,1 &#x000b1; 14,8&#x02009;U/L versus 59,6&#x02009;U/L (<italic>p</italic> &#x0003c; 0,001).<italic> Conclusion</italic>. Melatonin exerts a hepatoprotective effect in patients taking statins.</p></abstract><funding-group><award-group><funding-source>Ministerstwo Nauki i Szkolnictwa Wyzszego</funding-source><award-id>NN 402 54 37/40</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Statins are widely used in the treatment and prevention of lipid metabolism disorders [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. They are generally well tolerated but not devoid of side effects [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. These include, among others, muscular symptoms, arthritis, headaches, and gynecomastia. Myositis and rhabdomyolysis associated with increased activity of creatinine kinase and serum creatinine levels are rare but serious adverse events of statin therapy [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. The risk of these complications is increased in elderly patients with chronic diseases and in alcohol abusers [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>Furthermore, statins cause hepatotoxic effect which is observed in several percent of treated patients, usually in the first weeks of the therapy [<xref rid="B8" ref-type="bibr">8</xref>&#x02013;<xref rid="B10" ref-type="bibr">10</xref>]. Most frequently it is manifested by asymptomatic increase in the level of aspartate and alanine aminotransferase [<xref rid="B11" ref-type="bibr">11</xref>]. This is usually a temporary increase, but in some patients the level of these enzymes exceeds 3 times the normal limit, which is a matter of concern [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. In such cases, patients expect the decision to discontinue the treatment or to administer hepatoprotective drugs [<xref rid="B14" ref-type="bibr">14</xref>]. Acetylcholine, silibinin, phospholipids, and other drugs used for this purpose are not always effective. Therefore, there is still search for alternative drugs for the protection of liver.</p><p>In our study melatonin was used for this purpose because previous experimental studies had demonstrated that it protected liver against harmful effects of many toxic agents [<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>] as well as the consequences of ischemia-reperfusion model [<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>].</p><p>The liver is an organ in which intensive metabolic and detoxification processes take place. In their course large amounts of reactive oxygen species are generated and they exert a toxic effect on hepatocytes. A complex antioxidant system, in which metabolized there melatonin (pineal and from other sources) is an important part, prevents that [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>].</p><p>The main melatonin metabolic pathway in the liver is through hydroxylation pathway at the C-6 position by 6-hydroxylase and P450 cytochromes (CYP1A1, CYP1A2, CYP2P19, and CYP1B1 isozymes) [<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>]. The 6-hydroxymelatonin, formed in this process, is conjugated with sulphate and glucuronide to 6-hydroxymelatonin sulphate or glucuronide. In this process melatonin and its metabolites exert high antioxidant activity.</p><p>An alternative metabolic pathway includes melatonin oxidation to N-acetyl-formyl-5-methoxykynuramine (AFMK) and N-acetyl-5-methoxykynuramine (AMK). The kynurenine pathway of melatonin metabolism leads to formation of a series of free radical scavengers [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>].</p><p>Furthermore, melatonin decreases the production of proinflammatory cytokines [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>] and inhibits hepatic fibrogenesis [<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>]. Owing to its multidirectional action in liver, apoptosis and necrosis decrease, the integrity is protected, and regeneration is improved [<xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B38" ref-type="bibr">38</xref>].</p><p>The aim of this study was to assess the usefulness of melatonin in counteracting the adverse hepatic events from statins.</p></sec><sec id="sec2"><title>2. Material and Methods</title><sec id="sec2.1"><title>2.1. Patients and Data Collection</title><p>The research program included 60 subjects, aged 47&#x02013;68 years, 41 women and 19 men.&#x02009;&#x02009;All women were postpostmenopausal. Recruitment and diagnostic tests were conducted in the Department of Gastroenterology, Medical University of Lodz, and Outpatient Consulting Clinic &#x0201c;Gastro&#x0201d; in Lodz.</p><p>The research study was performed in the years 2012&#x02013;2016.</p><p> Inclusion criteria are as follows:<list list-type="roman-lower"><list-item><p>Hyperlipidemia treated with statins for minimum of 6 months</p></list-item><list-item><p>At least 2-fold increase in the level of aspartate and alanine aminotransferase found in two consecutive tests</p></list-item><list-item><p>The persistence of increased aminotransferase levels despite the reduction in the statin dose</p></list-item></list>At the time of the inclusion of patients in the study, 38 subjects were taking atorvastatin (20&#x02009;mg) and 26 rosuvastatin at the dose of 40&#x02009;mg (3 patients), 20&#x02009;mg (19 patients), and 15&#x02009;mg (4 patients).</p><p> Exclusion criteria are as follows:<list list-type="roman-lower"><list-item><p>History of viral hepatitis</p></list-item><list-item><p>Cholelithiasis</p></list-item><list-item><p>Body mass index (BMI) &#x0003e; 30&#x02009;kg/m<sup>2</sup></p></list-item><list-item><p>Alcohol abuse</p></list-item><list-item><p>Familial hypercholesterolemia</p></list-item><list-item><p>Established hypertension</p></list-item><list-item><p>Thyroid diseases</p></list-item><list-item><p>Other organic, metabolic, or mental diseases</p></list-item><list-item><p>Hormone replacement therapy</p></list-item><list-item><p>Taking other medications, especially analgesics and psychotropic drugs</p></list-item></list></p></sec><sec id="sec2.2"><title>2.2. Laboratory Tests</title><p>The following biochemical parameters using standard automated technique were assessed: blood cells count and levels of bilirubin, aspartate (AST) and alanine (ALT) aminotransferase, gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total and LDL and HDL cholesterol, triglycerides, glucose, amylase, lipase, urea, creatinine, acute phase protein, thyroid stimulating hormone (TSH), and follicle-stimulating hormone (FSH) in serum.</p></sec><sec id="sec2.3"><title>2.3. Therapeutic Procedures</title><p>After inclusion into the study, all patients were recommended the same balanced diet with limited animal fats and simple carbohydrates of caloric content of 1600&#x02009;kcal. At the same time, they were recommended to continue the treatment with the same statin at a daily dose of 20&#x02009;mg.</p><p>The patients were randomly allocated into two groups. Group I (<italic>n</italic> = 30) was recommended to take statin together with melatonin (LEK-AM, Poland) at a dose of 2 &#x000d7; 5&#x02009;mg, at 7:00&#x02009;a.m. and 9:00&#x02009;p.m. In Group II (<italic>n</italic> = 30) patients took statin with placebo (LEK-AM, Poland) at the same dose and time of the day.</p><p>Follow-up laboratory tests (AST, ALT, GGT, ALP, cholesterol, and triglycerides) were evaluated after 2, 4, and 6 months of treatment.</p></sec><sec id="sec2.4"><title>2.4. Ethical Procedures</title><p>A written consent was obtained from the patients and the Bioethics Committee of the Medical University in Lodz approved the study protocol (RNN/45/12/KB).</p><p>Tests were conducted in accordance with the Declaration of Helsinki and with the principles of Good Clinical Practice.</p></sec><sec id="sec2.5"><title>2.5. Statistical Analysis</title><p>All parameters were checked for normality using the Shapiro-Wilk test. Wilcoxon's rank sum test was used for the comparison of basal treatment differences between each liver enzyme level. Comparison of parameters in four time series was calculated using ANOVA Friedman test. Mann&#x02013;Whitney <italic>U</italic> test was used for nonparametric data to perform the comparison between groups. Calculations were made using Statistical 9.1 Microsoft Co. software, and statistical significance was established at <italic>p</italic> &#x0003c; 0,05.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>In Group I the initial level of aspartate aminotransferase was 97.2 &#x000b1; 19.1&#x02009;U/L. After introduction of melatonin to the treatment this level decreased after 2 months to 77.5 &#x000b1; 10.9&#x02009;U/L (<italic>p</italic> &#x0003c; 0.05) and it remained at a similar level after 4 months 66.2 &#x000b1; 10.3&#x02009;U/L (<italic>p</italic> &#x0003c; 0.01) and after 6 months 52.8 &#x000b1; 13.3&#x02009;U/L (<italic>p</italic> &#x0003c; 0.001).</p><p>In Group II treated with statin and placebo, the AST level in the same time intervals was, respectively, 95.7 &#x000b1; 16.3&#x02009;U/L, 85.8 &#x000b1; 14.5&#x02009;U/L, 84.8 &#x000b1; 12.5&#x02009;U/L, and 87.5 &#x000b1; 13.7&#x02009;U/L; the differences were not statistically significant (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Alanine aminotransferase level was in Group I in the same time intervals, respectively, 87.4 &#x000b1; 15.6&#x02009;U/L, 65.2 &#x000b1; 13.9&#x02009;U/L (<italic>p</italic> &#x0003c; 0.01), 55.2 &#x000b1; 11.1&#x02009;U/L (<italic>p</italic> &#x0003c; 0.001), and 49.8 &#x000b1; 14.5&#x02009;U/L (<italic>p</italic> &#x0003c; 0.001).</p><p>However, in Group II, ALT level did not change significantly during the treatment and it was, respectively, 87.5 &#x000b1; 15.7&#x02009;U/L, 80.9 &#x000b1; 11.3&#x02009;U/L, 80.5 &#x000b1; 13.2&#x02009;U/L, and 84.2 &#x000b1; 14.6&#x02009;U/L (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>The level of gamma-glutamyltransferase was in group receiving melatonin, respectively, 84.1 &#x000b1; 14.8&#x02009;U/L, 71.5 &#x000b1; 14.3&#x02009;U/L (<italic>p</italic> &#x0003e; 0.05), 62.8 &#x000b1; 11.3&#x02009;U/L (<italic>p</italic> &#x0003e; 0.05), and 59.6 &#x000b1; 8.3&#x02009;U/L (<italic>p</italic> &#x0003c; 0.01). In Group II, these values were, respectively, 75.9 &#x000b1; 11.3&#x02009;U/L, 72.9 &#x000b1; 9.7&#x02009;U/L, 69.9 &#x000b1; 7.9&#x02009;U/L, and 70.9 &#x000b1; 9.2&#x02009;U/L; the differences were statistically insignificant (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>The level of alkaline phosphatase varied in both groups from 58.0 to 142.6&#x02009;U/L and only in two patients in Group I and two in Group II patients it exceeded the upper limit of normal range of 120&#x02009;U/L. These values returned to normal after 2 and 4 months of treatment only in Group I (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>After 6 months the decrease of all enzyme levels was significantly higher in Group I compared to Group II (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>After 6 months normal AST values were observed in 8 (25,0%), ALT in 9 (28,1%), and GGT in 11 (34,3%) on Group I patients.</p><p>In Group II, after 6 months, normal results were found only in 1 patient (3,7%), whereas in 6 of them AST and ALT level increased by the average of 11,3%.</p><p>In Group I, the level of total cholesterol decreased after 6 months from 254.2 &#x000b1; 20.2&#x02009;mg/dL to 212.6 &#x000b1; 19.6&#x02009;mg/dL and in Group II from 245.6 &#x000b1; 16.4&#x02009;mg/dL to 226.3 &#x000b1; 20.7&#x02009;mg/dL; differences between the groups were statistically significant (<italic>p</italic> &#x0003c; 0.05).</p><p>Triglyceride level decreased in Group I from 212,4 &#x000b1; 20,3&#x02009;mg/dL to 183,0 &#x000b1; 14,6&#x02009;mg/dL and in Group II from 193.6 &#x000b1; 20,1&#x02009;mg/dL to 171,4 &#x000b1; 15,4&#x02009;mg/dL; the differences between the groups were insignificant (<italic>p</italic> &#x0003e; 0,05).</p><p>All drugs were well tolerated. Patients did not complain of any ailments that could result from side effects before treatment or during its continuation. The exception was 6 patients from Group I, who in the first two weeks of taking melatonin felt mild fatigue in the morning hours.</p></sec><sec id="sec4"><title>4. Discussion</title><p>The task of the liver is to transform the lipophilic drugs into hydrophilic compounds, which are excreted in the bile or urine. To this purpose, the drugs undergo oxidation processes by cytochrome P450 isozymes and by conjugation mainly with sulfuric and glucuronic acid or with glutathione. In the oxidation reaction, together with chemically stable metabolites, there may appear reactive metabolites which damage hepatocytes by two main mechanisms.</p><p>The first mechanism is immune idiosyncrasy, a reaction involving a metabolite and the enzyme responsible for its formation, usually with an appropriate cytochrome P450. Such a protein complex becomes a new antigen which is transported to the hepatocyte surface. There, cellular and humoral immune response is induced, directed against antigen-presenting cells, which is manifested within a few weeks [<xref rid="B39" ref-type="bibr">39</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>].</p><p>In the second mechanism, which is a reaction of metabolic hypersensitivity (metabolic idiosyncrasy) immune processes are not present. In this mechanism latency period is usually longer and it may be even several months [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>].</p><p>The direct drug-induced injury by molecular mechanisms is the opposite of idiosyncrasy. High concentration of a drug or its metabolite leads to the inactivation of many important cytoplasmic or mitochondrial proteins. Drugs can also disturb the processes of mitochondrial fatty acid oxidation or inhibit the activity of the respiratory chain. This results in metabolic changes such as hypertriglyceridemia, decrease in ATP production, and increased production of oxygen free radicals [<xref rid="B44" ref-type="bibr">44</xref>&#x02013;<xref rid="B46" ref-type="bibr">46</xref>].</p><p>The mechanism of statin-related hepatotoxicity is not clear. It is suggested that statins cause damage to mitochondrial membranes which leads to the leakage of aminotransferases [<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>]. Statin lipophilicity may play an important role. Statins of low lipophilicity (fluvastatin, rosuvastatin, and atorvastatin) more frequently cause the increase in aminotransferase levels compared to statins of higher lipophilicity (levostatin, simvastatin) [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>].</p><p>Statins even at low doses may lead to hepatocellular damage; however, this happens more often at high dose [<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>]. An optimal dose of melatonin, which should be administered in different stages of diseases is a debatable issue. Harps&#x000f8;e et al. [<xref rid="B53" ref-type="bibr">53</xref>] reviewed 392 literature records and found out that the applied melatonin doses ranged from 0.3&#x02009;mg to 100&#x02009;mg/daily. In order to control the sleep the most frequently recommended dose was 1&#x02013;3&#x02009;mg per night [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>]. The dose of 3 and 5&#x02009;mg was used in the treatment of alimentary tract functional and inflammatory disorders [<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B60" ref-type="bibr">60</xref>] and in the treatment of headaches only 10&#x02009;mg proved to be effective [<xref rid="B61" ref-type="bibr">61</xref>].</p><p>In the case of patients with nonalcoholic steatohepatitis (NASH), Gonciarz et al. [<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>] administered melatonin at a dose of 2 &#x000d7; 5&#x02009;mg for 3 months. The follow-up after 4, 8, and 12 weeks showed the decrease in the level of liver enzymes (AST &#x0003c; ALT and GGT) and this continued for further 12 weeks. Cichoz-Lach et al. [<xref rid="B64" ref-type="bibr">64</xref>], also in patients with NASH, used melatonin (2 &#x000d7; 5&#x02009;mg) for 4 weeks and they also found the decreased level of liver enzymes and triglycerides and proinflammatory cytokines. Cardineli and Hadeland [<xref rid="B65" ref-type="bibr">65</xref>] suggested a melatonin dose of 50&#x02013;100&#x02009;mg/daily for the regulation of inflammatory and metabolic disorders. Such high single doses of melatonin were given to patients before liver transplantation and its good tolerability and a positive impact on the postoperative condition were demonstrated and it was expressed, among others, by faster drop in AST and ALT compared to placebo [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>].</p><p>Good tolerability and safety of melatonin result from its pharmacokinetic properties. Andersen et al. [<xref rid="B68" ref-type="bibr">68</xref>] administered intravenously 10 or 100&#x02009;mg of melatonin to 12 healthy volunteers, obtaining its maximum serum concentrations of 185,637 and 1,770,500&#x02009;pg/mL at T1/2, 43.3 and 46.2 minutes, with the absence of any side effects. The same researchers [<xref rid="B69" ref-type="bibr">69</xref>] administered orally 10&#x02009;mg of melatonin to the volunteers and found its maximum serum concentration of 3550&#x02009;pg/mL at T1/2, 53.7&#x02009;min. Similar results of the studies on melatonin pharmacokinetics were obtained by other researchers who used the oral dose of 0.4&#x02009;mg and 4&#x02009;mg in older adults [<xref rid="B70" ref-type="bibr">70</xref>] and 80&#x02009;mg in young male volunteers [<xref rid="B71" ref-type="bibr">71</xref>]. Thus, a single administration of melatonin raises its level for only a few hours. This justifies the administration of melatonin in divided doses in order to take full advantage of its hepatoprotective effect, particularly in metabolic disorders. Metabolic syndrome belongs to such conditions, since the results of experimental [<xref rid="B72" ref-type="bibr">72</xref>&#x02013;<xref rid="B74" ref-type="bibr">74</xref>] and clinical studies [<xref rid="B75" ref-type="bibr">75</xref>&#x02013;<xref rid="B80" ref-type="bibr">80</xref>] confirm the beneficial effect of melatonin.</p><p>Our results confirm significant hepatoprotective effect of melatonin in patients treated with statins. Medications regulating lipid metabolism are taken chronically and therefore hepatoprotective factors should be used on long-term basis and should be free of side effects; melatonin satisfies such conditions.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>The conclusions from the obtained results support the opinion of many researchers that melatonin can be administered to protect against side effects of other drugs.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the grant from the Polish Ministry of Science and Higher Education no. NN 402 54 37/40.</p></ack><sec><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>G. B. J.</given-names></name><name><surname>Baker</surname><given-names>S.</given-names></name><name><surname>Bergeron</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a canadian working group consensus conference</article-title><source><italic>Canadian Journal of Cardiology</italic></source><year>2011</year><volume>27</volume><issue>5</issue><fpage>635</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2011.05.007</pub-id><pub-id pub-id-type="other">2-s2.0-81255165866</pub-id><pub-id pub-id-type="pmid">21963058</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eslami</surname><given-names>L.</given-names></name><name><surname>Merat</surname><given-names>S.</given-names></name><name><surname>Malekzadeh</surname><given-names>R.</given-names></name><name><surname>Nasseri-Moghaddam</surname><given-names>S.</given-names></name><name><surname>Aramin</surname><given-names>H.</given-names></name></person-group><article-title>Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis</article-title><source><italic>The Cochrane Database of Systematic Reviews</italic></source><year>2013</year><volume>27</volume><issue>12</issue><pub-id pub-id-type="publisher-id">CD008623</pub-id><pub-id pub-id-type="doi">10.1002/14651858.CD008623</pub-id><pub-id pub-id-type="other">2-s2.0-84897368255</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banach</surname><given-names>M.</given-names></name><name><surname>Rizzo</surname><given-names>M.</given-names></name><name><surname>Toth</surname><given-names>P. P.</given-names></name><etal/></person-group><article-title>Statin intolerance &#x02013; an attempt at a unified definition. Position paper from an international lipid expert panel</article-title><source><italic>Archives of Medical Science</italic></source><year>2015</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1517/14740338.2015.1039980</pub-id><pub-id pub-id-type="pmid">25861286</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxon</surname><given-names>D. R.</given-names></name><name><surname>Eckel</surname><given-names>R. H.</given-names></name></person-group><article-title>Statin intolerance: a literature review and management strategies</article-title><source><italic>Progress in Cardiovascular Diseases</italic></source><year>2016</year><volume>59</volume><issue>2</issue><fpage>153</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2016.07.009</pub-id><pub-id pub-id-type="pmid">27497504</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schalke</surname><given-names>B. B.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><name><surname>Toyka</surname><given-names>K.</given-names></name><name><surname>Hartung</surname><given-names>H.-P.</given-names></name><name><surname>Hayes</surname><given-names>T. A.</given-names></name><name><surname>Frau</surname><given-names>L. M.</given-names></name></person-group><article-title>Pravastatin-associated inflammatory myopathy</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1992</year><volume>327</volume><issue>9</issue><fpage>649</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1056/NEJM199208273270919</pub-id><pub-id pub-id-type="other">2-s2.0-0026722199</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molokhia</surname><given-names>M.</given-names></name><name><surname>McKeigue</surname><given-names>P.</given-names></name><name><surname>Curcin</surname><given-names>V.</given-names></name><name><surname>Majeed</surname><given-names>A.</given-names></name></person-group><article-title>Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991&#x02013;2006</article-title><source><italic>PLoS ONE</italic></source><year>2008</year><volume>3</volume><issue>6</issue><pub-id pub-id-type="publisher-id">e2522</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002522</pub-id><pub-id pub-id-type="other">2-s2.0-49649119693</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitzur</surname><given-names>R.</given-names></name><name><surname>Cohen</surname><given-names>H.</given-names></name><name><surname>Kamari</surname><given-names>Y.</given-names></name><name><surname>Harats</surname><given-names>D.</given-names></name></person-group><article-title>Intolerance to statins: mechanisms and management</article-title><source><italic>Diabetes Care</italic></source><year>2013</year><volume>36</volume><issue>2</issue><fpage>S325</fpage><lpage>S330</lpage><pub-id pub-id-type="doi">10.2337/dcS13-2038</pub-id><pub-id pub-id-type="other">2-s2.0-84891804222</pub-id><pub-id pub-id-type="pmid">23882066</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapar</surname><given-names>M.</given-names></name><name><surname>Russo</surname><given-names>M.</given-names></name><name><surname>Bonkovsky</surname><given-names>H. L.</given-names></name></person-group><article-title>Statins and liver injury</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>2013</year><volume>9</volume><issue>9</issue><fpage>605</fpage><lpage>606</lpage><pub-id pub-id-type="other">2-s2.0-84887851180</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadranel</surname><given-names>J.-F.</given-names></name><name><surname>Seddik</surname><given-names>M.</given-names></name><name><surname>Loric</surname><given-names>S.</given-names></name><name><surname>Jeanne</surname><given-names>S.</given-names></name></person-group><article-title>Statins: hepatotoxicity and monitoring</article-title><source><italic>Presse Medicale</italic></source><year>2009</year><volume>38</volume><issue>5</issue><fpage>717</fpage><lpage>725</lpage><pub-id pub-id-type="other">2-s2.0-65649114754</pub-id><pub-id pub-id-type="doi">10.1016/j.lpm.2008.05.022</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jose</surname><given-names>J.</given-names></name></person-group><article-title>Statins and its hepatic effects: Newer data, implications, and changing recommendations</article-title><source><italic>Journal of Pharmacy and Bioallied Sciences</italic></source><year>2016</year><volume>8</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="other">2-s2.0-84955445737</pub-id><pub-id pub-id-type="doi">10.4103/0975-7406.171699</pub-id><pub-id pub-id-type="pmid">26957864</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalasani</surname><given-names>N.</given-names></name><name><surname>Aljadhey</surname><given-names>H.</given-names></name><name><surname>Kesterson</surname><given-names>J.</given-names></name><name><surname>Murray</surname><given-names>M. D.</given-names></name><name><surname>Hall</surname><given-names>S. D.</given-names></name></person-group><article-title>Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity</article-title><source><italic>Gastroenterology</italic></source><year>2004</year><volume>126</volume><issue>5</issue><fpage>1287</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.02.015</pub-id><pub-id pub-id-type="other">2-s2.0-2142768218</pub-id><pub-id pub-id-type="pmid">15131789</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>J.</given-names></name></person-group><article-title>The safety of statins in clinical practice</article-title><source><italic>The Lancet</italic></source><year>2007</year><volume>370</volume><issue>9601</issue><fpage>1781</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(07)60716-8</pub-id><pub-id pub-id-type="other">2-s2.0-35748962429</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arca</surname><given-names>M.</given-names></name><name><surname>Pigna</surname><given-names>G.</given-names></name></person-group><article-title>Treating statin-intolerant patients</article-title><source><italic>Diabetes, Metabolic Syndrome and Obesity</italic></source><year>2011</year><volume>4</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.2147/DMSO.S11244</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderon</surname><given-names>R. M.</given-names></name><name><surname>Cubeddu</surname><given-names>L. X.</given-names></name><name><surname>Goldberg</surname><given-names>R. B.</given-names></name><name><surname>Schiff</surname><given-names>E. R.</given-names></name></person-group><article-title>Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma</article-title><source><italic>Mayo Clinic Proceedings</italic></source><year>2010</year><volume>85</volume><issue>4</issue><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.4065/mcp.2009.0365</pub-id><pub-id pub-id-type="other">2-s2.0-77950625119</pub-id><pub-id pub-id-type="pmid">20360293</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shokrzadeh</surname><given-names>M.</given-names></name><name><surname>Ahmadi</surname><given-names>A.</given-names></name><name><surname>Naghshvar</surname><given-names>F.</given-names></name><name><surname>Chabra</surname><given-names>A.</given-names></name><name><surname>Jafarinejhad</surname><given-names>M.</given-names></name></person-group><article-title>Prophylactic efficacy of melatonin on cyclophosphamide-induced liver toxicity in mice</article-title><source><italic>BioMed Research International</italic></source><year>2014</year><volume>2014</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">470425</pub-id><pub-id pub-id-type="doi">10.1155/2014/470425</pub-id><pub-id pub-id-type="other">2-s2.0-84904736788</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San-Miguel</surname><given-names>B.</given-names></name><name><surname>Crespo</surname><given-names>I.</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>D. I.</given-names></name><etal/></person-group><article-title>Melatonin inhibits autophagy and endoplasmic reticulum stress in mice with carbon tetrachloride-induced fibrosis</article-title><source><italic>Journal of Pineal Research</italic></source><year>2015</year><volume>59</volume><issue>2</issue><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="other">2-s2.0-84938345083</pub-id><pub-id pub-id-type="doi">10.1111/jpi.12247</pub-id><pub-id pub-id-type="pmid">25958928</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiao</surname><given-names>M.-M.</given-names></name><name><surname>Huang</surname><given-names>L.-T.</given-names></name><name><surname>Chen</surname><given-names>C.-J.</given-names></name><etal/></person-group><article-title>Melatonin in the regulation of liver steatosis following prenatal glucocorticoid exposure</article-title><source><italic>BioMed Research International</italic></source><year>2014</year><volume>2014</volume><fpage>9</fpage><pub-id pub-id-type="publisher-id">942172</pub-id><pub-id pub-id-type="doi">10.1155/2014/942172</pub-id><pub-id pub-id-type="other">2-s2.0-84900035445</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteban-Zubero</surname><given-names>E.</given-names></name><name><surname>Alatorre-Jim&#x000e9;nez</surname><given-names>M. A.</given-names></name><name><surname>L&#x000f3;pez-Pingarr&#x000f3;n</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Melatonin's role in preventing toxin-related and sepsis-mediated hepatic damage: a review</article-title><source><italic>Pharmacological Research</italic></source><year>2016</year><volume>105</volume><fpage>108</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.01.018</pub-id><pub-id pub-id-type="other">2-s2.0-84956717504</pub-id><pub-id pub-id-type="pmid">26808084</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J.-W.</given-names></name><name><surname>Cho</surname><given-names>H.-I.</given-names></name><name><surname>Lee</surname><given-names>S.-M.</given-names></name></person-group><article-title>Melatonin inhibits mTOR-dependent autophagy during liver ischemia/reperfusion</article-title><source><italic>Cellular Physiology and Biochemistry</italic></source><year>2014</year><volume>33</volume><issue>1</issue><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="other">2-s2.0-84891709303</pub-id><pub-id pub-id-type="doi">10.1159/000356647</pub-id><pub-id pub-id-type="pmid">24401531</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gim</surname><given-names>S.-A.</given-names></name><name><surname>Koh</surname><given-names>P.-O.</given-names></name></person-group><article-title>Melatonin attenuates hepatic ischemia through mitogen-activated protein kinase signaling</article-title><source><italic>Journal of Surgical Research</italic></source><year>2015</year><volume>198</volume><issue>1</issue><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="other">2-s2.0-84938744795</pub-id><pub-id pub-id-type="doi">10.1016/j.jss.2015.05.043</pub-id><pub-id pub-id-type="pmid">26101163</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.-H.</given-names></name><name><surname>Chen</surname><given-names>Y.-T.</given-names></name><name><surname>Yang</surname><given-names>C.-C.</given-names></name><etal/></person-group><article-title>Melatonin pretreatment enhances the therapeutic effects of exogenous mitochondria against hepatic ischemia-reperfusion injury in rats through suppression of mitochondrial permeability transition</article-title><source><italic>Journal of Pineal Research</italic></source><year>2016</year><volume>61</volume><issue>1</issue><fpage>52</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/jpi.12326</pub-id><pub-id pub-id-type="other">2-s2.0-84978121068</pub-id><pub-id pub-id-type="pmid">26993080</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>E. A.</given-names></name><name><surname>Moss</surname><given-names>H. B.</given-names></name></person-group><article-title>Pharmacokinetics of melatonin in man: first pass hepatic metabolism</article-title><source><italic>Journal of Clinical Endocrinology &#x00026; Metabolism</italic></source><year>1985</year><volume>61</volume><issue>6</issue><fpage>1214</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1210/jcem-61-6-1214</pub-id><pub-id pub-id-type="pmid">4055987</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>R. J.</given-names></name><name><surname>Rosales-Corral</surname><given-names>S. A.</given-names></name><name><surname>Manchester</surname><given-names>L. C.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Tan</surname><given-names>D.-X.</given-names></name></person-group><article-title>Melatonin in the biliary tract and liver: health implications</article-title><source><italic>Current Pharmaceutical Design</italic></source><year>2014</year><volume>20</volume><issue>30</issue><fpage>4788</fpage><lpage>4801</lpage><pub-id pub-id-type="doi">10.2174/1381612819666131119105826</pub-id><pub-id pub-id-type="other">2-s2.0-84906260661</pub-id><pub-id pub-id-type="pmid">24251672</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Facciol&#x000e1;</surname><given-names>G.</given-names></name><name><surname>Hidestrand</surname><given-names>M.</given-names></name><name><surname>Von Bahr</surname><given-names>C.</given-names></name><name><surname>Tybring</surname><given-names>G.</given-names></name></person-group><article-title>Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes</article-title><source><italic>European Journal of Clinical Pharmacology</italic></source><year>2001</year><volume>56</volume><issue>12</issue><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="other">2-s2.0-0035293495</pub-id><pub-id pub-id-type="doi">10.1007/s002280000245</pub-id><pub-id pub-id-type="pmid">11317475</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X. C.</given-names></name><name><surname>Idle</surname><given-names>J. R.</given-names></name><name><surname>Krausz</surname><given-names>K. W.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name></person-group><article-title>Metabolism of melatonin by human cytochromes P450</article-title><source><italic>Drug Metabolism and Disposition</italic></source><year>2005</year><volume>33</volume><issue>4</issue><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.002410</pub-id><pub-id pub-id-type="other">2-s2.0-15344344226</pub-id><pub-id pub-id-type="pmid">15616152</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letelier</surname><given-names>M. E.</given-names></name><name><surname>Jara-Sandoval</surname><given-names>J.</given-names></name><name><surname>Molina-Berr&#x000ed;os</surname><given-names>A.</given-names></name><name><surname>Fa&#x000fa;ndez</surname><given-names>M.</given-names></name><name><surname>Aracena-Parks</surname><given-names>P.</given-names></name><name><surname>Aguilera</surname><given-names>F.</given-names></name></person-group><article-title>Melatonin protects the cytochrome P450 system through a novel antioxidant mechanism</article-title><source><italic>Chemico-Biological Interactions</italic></source><year>2010</year><volume>185</volume><issue>3</issue><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="other">2-s2.0-77952301614</pub-id><pub-id pub-id-type="doi">10.1016/j.cbi.2010.03.020</pub-id><pub-id pub-id-type="pmid">20302852</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harth&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Claudy</surname><given-names>D.</given-names></name><name><surname>D&#x000e9;chaud</surname><given-names>H.</given-names></name><name><surname>Vivien-Roels</surname><given-names>B.</given-names></name><name><surname>P&#x000e9;vet</surname><given-names>P.</given-names></name><name><surname>Claustrat</surname><given-names>B.</given-names></name></person-group><article-title>Radioimmunoassay of N-acetyl-N-formyl-5-methoxykynuramine (AFMK): a melatonin oxidative metabolite</article-title><source><italic>Life Sciences</italic></source><year>2003</year><volume>73</volume><issue>12</issue><fpage>1587</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(03)00483-1</pub-id><pub-id pub-id-type="other">2-s2.0-0037966074</pub-id><pub-id pub-id-type="pmid">12865098</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galano</surname><given-names>A.</given-names></name><name><surname>Tan</surname><given-names>D. X.</given-names></name><name><surname>Reiter</surname><given-names>R. J.</given-names></name></person-group><article-title>On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK</article-title><source><italic>Journal of Pineal Research</italic></source><year>2013</year><volume>54</volume><issue>3</issue><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1111/jpi.12010</pub-id><pub-id pub-id-type="other">2-s2.0-84874949228</pub-id><pub-id pub-id-type="pmid">22998574</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinrinmade</surname><given-names>F. J.</given-names></name><name><surname>Akinrinde</surname><given-names>A. S.</given-names></name><name><surname>Amid</surname><given-names>A.</given-names></name></person-group><article-title>Changes in serum cytokine levels, hepatic and intestinal morphology in aflatoxin B1-induced injury: modulatory roles of melatonin and flavonoid-rich fractions from Chromolena odorata</article-title><source><italic>Mycotoxin Research</italic></source><year>2016</year><volume>32</volume><issue>2</issue><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="other">2-s2.0-84955265017</pub-id><pub-id pub-id-type="doi">10.1007/s12550-016-0239-9</pub-id><pub-id pub-id-type="pmid">26798045</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laliena</surname><given-names>A.</given-names></name><name><surname>Miguel</surname><given-names>B. S.</given-names></name><name><surname>Crespo</surname><given-names>I.</given-names></name><name><surname>Alvarez</surname><given-names>M.</given-names></name><name><surname>Gonz&#x000e1;lez-Gallego</surname><given-names>J.</given-names></name><name><surname>Tu&#x000f1;&#x000f3;n</surname><given-names>M. J.</given-names></name></person-group><article-title>Melatonin attenuates inflammation and promotes regeneration in rabbits with fulminant hepatitis of viral origin</article-title><source><italic>Journal of Pineal Research</italic></source><year>2012</year><volume>53</volume><issue>3</issue><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1111/j.1600-079x.2012.00995.x</pub-id><pub-id pub-id-type="other">2-s2.0-84866264682</pub-id><pub-id pub-id-type="pmid">22506987</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czechowska</surname><given-names>G.</given-names></name><name><surname>Celinski</surname><given-names>K.</given-names></name><name><surname>Korolczuk</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protective effects of melatonin against thioacetamide-induced liver fibrosis in rats</article-title><source><italic>Journal of Physiology and Pharmacology</italic></source><year>2015</year><volume>66</volume><issue>4</issue><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="other">2-s2.0-84940784003</pub-id><pub-id pub-id-type="pmid">26348081</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Melatonin: the dawning of a treatment for fibrosis?</article-title><source><italic>Journal of Pineal Research</italic></source><year>2016</year><volume>60</volume><issue>2</issue><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1111/jpi.12302</pub-id><pub-id pub-id-type="pmid">26680689</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J.-W.</given-names></name><name><surname>Hong</surname><given-names>J.-M.</given-names></name><name><surname>Lee</surname><given-names>S.-M.</given-names></name></person-group><article-title>Melatonin enhances mitophagy and mitochondrial biogenesis in rats with carbon tetrachloride-induced liver fibrosis</article-title><source><italic>Journal of Pineal Research</italic></source><year>2016</year><volume>60</volume><issue>4</issue><fpage>383</fpage><lpage>393</lpage><pub-id pub-id-type="other">2-s2.0-84960156771</pub-id><pub-id pub-id-type="doi">10.1111/jpi.12319</pub-id><pub-id pub-id-type="pmid">26882442</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shajari</surname><given-names>S.</given-names></name><name><surname>Laliena</surname><given-names>A.</given-names></name><name><surname>Heegsma</surname><given-names>J.</given-names></name><name><surname>Tu&#x000f1;&#x000f5;n</surname><given-names>M. J.</given-names></name><name><surname>Moshage</surname><given-names>H.</given-names></name><name><surname>Faber</surname><given-names>K. N.</given-names></name></person-group><article-title>Melatonin suppresses activation of hepatic stellate cells through ROR<italic>&#x003b1;</italic>-mediated inhibition of 5-lipoxygenase</article-title><source><italic>Journal of Pineal Research</italic></source><year>2015</year><volume>59</volume><issue>3</issue><fpage>391</fpage><lpage>404</lpage><pub-id pub-id-type="other">2-s2.0-84942199329</pub-id><pub-id pub-id-type="doi">10.1111/jpi.12271</pub-id><pub-id pub-id-type="pmid">26308880</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y.-A.</given-names></name><name><surname>Noh</surname><given-names>K.</given-names></name><name><surname>Jue</surname><given-names>S.-S.</given-names></name><name><surname>Lee</surname><given-names>S.-Y.</given-names></name><name><surname>Kim</surname><given-names>E.-C.</given-names></name></person-group><article-title>Melatonin promotes hepatic differentiation of human dental pulp stem cells: clinical implications for the prevention of liver fibrosis</article-title><source><italic>Journal of Pineal Research</italic></source><year>2015</year><volume>58</volume><issue>1</issue><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1111/jpi.12198</pub-id><pub-id pub-id-type="other">2-s2.0-84919699269</pub-id><pub-id pub-id-type="pmid">25431168</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>M. A.</given-names></name><name><surname>del Carmen Contini</surname><given-names>M.</given-names></name><name><surname>Millen</surname><given-names>N.</given-names></name><name><surname>Mahieu</surname><given-names>S. T.</given-names></name></person-group><article-title>Role of melatonin in the oxidative damage prevention at different times of hepatic regeneration</article-title><source><italic>Cell Biochemistry and Function</italic></source><year>2012</year><volume>30</volume><issue>8</issue><fpage>701</fpage><lpage>708</lpage><pub-id pub-id-type="other">2-s2.0-84870688231</pub-id><pub-id pub-id-type="doi">10.1002/cbf.2855</pub-id><pub-id pub-id-type="pmid">22865586</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H.-S.</given-names></name><name><surname>Kang</surname><given-names>J.-W.</given-names></name><name><surname>Lee</surname><given-names>S.-M.</given-names></name></person-group><article-title>Melatonin attenuates carbon tetrachloride-induced liver fibrosis via inhibition of necroptosis</article-title><source><italic>Translational Research</italic></source><year>2015</year><volume>166</volume><issue>3</issue><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="other">2-s2.0-84938989183</pub-id><pub-id pub-id-type="doi">10.1016/j.trsl.2015.04.002</pub-id><pub-id pub-id-type="pmid">25936762</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacchiotti</surname><given-names>A.</given-names></name><name><surname>Favero</surname><given-names>G.</given-names></name><name><surname>Lavazza</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Hepatic macrosteatosis is partially converted to microsteatosis by melatonin supplementation in ob/ob mice non-alcoholic fatty liver disease</article-title><source><italic>PLoS ONE</italic></source><year>2016</year><volume>11</volume><issue>1</issue><pub-id pub-id-type="other">2-s2.0-84958267989</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148115</pub-id><pub-id pub-id-type="publisher-id">e0148115</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rnsson</surname><given-names>E.</given-names></name><name><surname>Jacobsen</surname><given-names>E. I.</given-names></name><name><surname>Kalaitzakis</surname><given-names>E.</given-names></name></person-group><article-title>Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing</article-title><source><italic>Journal of Hepatology</italic></source><year>2012</year><volume>56</volume><issue>2</issue><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.07.023</pub-id><pub-id pub-id-type="other">2-s2.0-84855970707</pub-id><pub-id pub-id-type="pmid">21889469</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussaini</surname><given-names>S. H.</given-names></name><name><surname>Farrington</surname><given-names>E. A.</given-names></name></person-group><article-title>Idiosyncratic drug-induced liver injury: an overview</article-title><source><italic>Expert Opinion on Drug Safety</italic></source><year>2007</year><volume>6</volume><issue>6</issue><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1517/14740338.6.6.673</pub-id><pub-id pub-id-type="other">2-s2.0-38449123465</pub-id><pub-id pub-id-type="pmid">17967156</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>C.</given-names></name><name><surname>Reilly</surname><given-names>T.</given-names></name></person-group><article-title>Role of immune reactions in drug-induced liver injury (DILI)</article-title><source><italic>Drug Metabolism Reviews</italic></source><year>2012</year><volume>44</volume><issue>1</issue><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="other">2-s2.0-84855889415</pub-id><pub-id pub-id-type="doi">10.3109/03602532.2011.645579</pub-id><pub-id pub-id-type="pmid">22235834</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>M. P.</given-names></name><name><surname>Ju</surname><given-names>C.</given-names></name></person-group><article-title>Mechanisms of drug-induced liver injury</article-title><source><italic>AAPS Journal</italic></source><year>2006</year><volume>8</volume><issue>1</issue><fpage>E48</fpage><lpage>E54</lpage><pub-id pub-id-type="doi">10.1208/aapsj080106</pub-id><pub-id pub-id-type="other">2-s2.0-33645799020</pub-id><pub-id pub-id-type="pmid">16584133</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tujios</surname><given-names>S.</given-names></name><name><surname>Fontana</surname><given-names>R. F.</given-names></name></person-group><article-title>Mechanisms of drug-induced liver injury: from bedside to bench</article-title><source><italic>Nature Reviews Gastroenterology &#x00026; Hepatology</italic></source><year>2011</year><volume>8</volume><issue>4</issue><fpage>202</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2011.22</pub-id><pub-id pub-id-type="pmid">21386809</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>M. W.</given-names></name><name><surname>Scobey</surname><given-names>M.</given-names></name><name><surname>Bonkovsky</surname><given-names>H. L.</given-names></name></person-group><article-title>Drug-induced liver injury associated with statins</article-title><source><italic>Seminars in Liver Disease</italic></source><year>2009</year><volume>29</volume><issue>4</issue><fpage>412</fpage><lpage>422</lpage><pub-id pub-id-type="other">2-s2.0-70449096299</pub-id><pub-id pub-id-type="doi">10.1055/s-0029-1240010</pub-id><pub-id pub-id-type="pmid">19826975</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stirnimann</surname><given-names>G.</given-names></name><name><surname>Kessebohm</surname><given-names>K.</given-names></name><name><surname>Lauterburg</surname><given-names>B.</given-names></name></person-group><article-title>Liver injury caused by drugs: an update</article-title><source><italic>Swiss Medical Weekly</italic></source><year>2010</year><volume>140</volume><pub-id pub-id-type="publisher-id">13080</pub-id><pub-id pub-id-type="doi">10.4414/smw.2010.13080</pub-id><pub-id pub-id-type="other">2-s2.0-78650604361</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>A.</given-names></name><name><surname>Figler</surname><given-names>R. A.</given-names></name><name><surname>Sanyal</surname><given-names>A. J.</given-names></name><etal/></person-group><article-title>Drug-induced steatohepatitis</article-title><source><italic>Expert Opinion on Drug Metabolism &#x00026; Toxicology</italic></source><year>2017</year><volume>13</volume><issue>2</issue><fpage>193</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1080/17425255.2017.1246534</pub-id><pub-id pub-id-type="pmid">27759439</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dujovne</surname><given-names>C. A.</given-names></name></person-group><article-title>Side effects of statins: hepatitis versus 'transaminitis'&#x02014;Myositis versus 'CPKitis'</article-title><source><italic>American Journal of Cardiology</italic></source><year>2002</year><volume>89</volume><issue>12</issue><fpage>1411</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(02)02356-1</pub-id><pub-id pub-id-type="other">2-s2.0-0037097447</pub-id><pub-id pub-id-type="pmid">12062737</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolosa</surname><given-names>L.</given-names></name><name><surname>Carmona</surname><given-names>A.</given-names></name><name><surname>Castell</surname><given-names>J. V.</given-names></name><name><surname>G&#x000f3;mez-Lech&#x000f3;n</surname><given-names>M. J.</given-names></name><name><surname>Donato</surname><given-names>M. T.</given-names></name></person-group><article-title>High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins</article-title><source><italic>Archives of Toxicology</italic></source><year>2015</year><volume>89</volume><issue>10</issue><fpage>1847</fpage><lpage>1860</lpage><pub-id pub-id-type="other">2-s2.0-84942117086</pub-id><pub-id pub-id-type="doi">10.1007/s00204-014-1334-3</pub-id><pub-id pub-id-type="pmid">25160661</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>K. M.</given-names></name><name><surname>White</surname><given-names>C. M.</given-names></name><name><surname>Henyan</surname><given-names>N. N.</given-names></name><name><surname>Kluger</surname><given-names>J.</given-names></name><name><surname>Coleman</surname><given-names>C. I.</given-names></name></person-group><article-title>Impact of statin dosing intensity on transaminase and creatine kinase</article-title><source><italic>American Journal of Medicine</italic></source><year>2007</year><volume>120</volume><issue>8</issue><fpage>706</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2006.07.033</pub-id><pub-id pub-id-type="other">2-s2.0-34547559566</pub-id><pub-id pub-id-type="pmid">17679130</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdices</surname><given-names>E. V.</given-names></name><name><surname>Medina-C&#x000e1;liz</surname><given-names>I.</given-names></name><name><surname>Hernando</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry</article-title><source><italic>Revista Espanola De Enfermedades Digestivas</italic></source><year>2014</year><volume>106</volume><issue>4</issue><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="other">2-s2.0-84919932448</pub-id><pub-id pub-id-type="pmid">25075655</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>A. T.</given-names></name><name><surname>Johnson</surname><given-names>P. C. D.</given-names></name><name><surname>Hall</surname><given-names>G. C.</given-names></name><name><surname>Ford</surname><given-names>I.</given-names></name><name><surname>Mills</surname><given-names>P. R.</given-names></name></person-group><article-title>High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort</article-title><source><italic>PLoS ONE</italic></source><year>2016</year><volume>11</volume><issue>3</issue><pub-id pub-id-type="other">2-s2.0-84978110444</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0151587</pub-id><pub-id pub-id-type="publisher-id">e0151587</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>M. H.</given-names></name><name><surname>Robinson</surname><given-names>J. G.</given-names></name></person-group><article-title>Safety of aggressive lipid management</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2007</year><volume>49</volume><issue>17</issue><fpage>1753</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.01.067</pub-id><pub-id pub-id-type="other">2-s2.0-34247267133</pub-id><pub-id pub-id-type="pmid">17466224</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harps&#x000f8;e</surname><given-names>N. G.</given-names></name><name><surname>Andersen</surname><given-names>L. P. H.</given-names></name><name><surname>G&#x000f6;genur</surname><given-names>I.</given-names></name><name><surname>Rosenberg</surname><given-names>J.</given-names></name></person-group><article-title>Clinical pharmacokinetics of melatonin: a systematic review</article-title><source><italic>European Journal of Clinical Pharmacology</italic></source><year>2015</year><volume>71</volume><issue>8</issue><fpage>901</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1007/s00228-015-1873-4</pub-id><pub-id pub-id-type="other">2-s2.0-84937736866</pub-id><pub-id pub-id-type="pmid">26008214</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>R. B.</given-names></name><name><surname>Lentino</surname><given-names>C. V.</given-names></name><name><surname>Boyd</surname><given-names>C. C.</given-names></name><etal/></person-group><article-title>The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature</article-title><source><italic>Nutrition Journal</italic></source><year>2014</year><volume>13</volume><issue>1, article 106</issue><pub-id pub-id-type="doi">10.1186/1475-2891-13-106</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Impact of oral melatonin on critically ill adult patients with ICU sleep deprivation: study protocol for a randomized controlled trial</article-title><source><italic>Trials</italic></source><year>2014</year><volume>15</volume><issue>1, article 327</issue><pub-id pub-id-type="doi">10.1186/1745-6215-15-327</pub-id><pub-id pub-id-type="other">2-s2.0-84929941212</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klupi&#x00144;ska</surname><given-names>G.</given-names></name><name><surname>Poplawski</surname><given-names>T.</given-names></name><name><surname>Drzewoski</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Therapeutic effect of melatonin in patients with functional dyspepsia</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2007</year><volume>41</volume><issue>3</issue><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="other">2-s2.0-33847371219</pub-id><pub-id pub-id-type="doi">10.1097/MCG.0b013e318031457a</pub-id><pub-id pub-id-type="pmid">17426465</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffari</surname><given-names>S.</given-names></name><name><surname>Rahimi</surname><given-names>R.</given-names></name><name><surname>Abdollahi</surname><given-names>M.</given-names></name></person-group><article-title>Implications of melatonin therapy in irritable bowel syndrome: a systematic review</article-title><source><italic>Current Pharmaceutical Design</italic></source><year>2010</year><volume>16</volume><issue>33</issue><fpage>3646</fpage><lpage>3655</lpage><pub-id pub-id-type="doi">10.2174/138161210794079254</pub-id><pub-id pub-id-type="other">2-s2.0-79954536320</pub-id><pub-id pub-id-type="pmid">21128901</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chojnacki</surname><given-names>C.</given-names></name><name><surname>Walecka-Kapica</surname><given-names>E.</given-names></name><name><surname>Lokie&#x00107;</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women</article-title><source><italic>Endokrynologia Polska</italic></source><year>2013</year><volume>64</volume><issue>2</issue><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="other">2-s2.0-84878135694</pub-id><pub-id pub-id-type="pmid">23653274</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siah</surname><given-names>K. T. H.</given-names></name><name><surname>Wong</surname><given-names>R. K. M.</given-names></name><name><surname>Ho</surname><given-names>K. Y.</given-names></name></person-group><article-title>Melatonin for the treatment of irritable bowel syndrome</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2014</year><volume>20</volume><issue>10</issue><fpage>2492</fpage><lpage>2498</lpage><pub-id pub-id-type="other">2-s2.0-84896805569</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v20.i10.2492</pub-id><pub-id pub-id-type="pmid">24627586</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jena</surname><given-names>G.</given-names></name><name><surname>Trivedi</surname><given-names>P. P.</given-names></name></person-group><article-title>A review of the use of melatonin in ulcerative colitis: experimental evidence and new approaches</article-title><source><italic>Inflammatory Bowel Diseases</italic></source><year>2014</year><volume>20</volume><issue>3</issue><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1097/01.MIB.0000436962.32164.6e</pub-id><pub-id pub-id-type="other">2-s2.0-84898740707</pub-id><pub-id pub-id-type="pmid">24247651</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelfand</surname><given-names>A. A.</given-names></name><name><surname>Goadsby</surname><given-names>P. J.</given-names></name></person-group><article-title>The role of melatonin in the treatment of primary headache disorders</article-title><source><italic>Headache Journals</italic></source><year>2016</year><volume>56</volume><issue>8</issue><fpage>1257</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1111/head.12862</pub-id><pub-id pub-id-type="other">2-s2.0-84978514911</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonciarz</surname><given-names>M.</given-names></name><name><surname>Gonciarz</surname><given-names>Z.</given-names></name><name><surname>Bielanski</surname><given-names>W.</given-names></name><etal/></person-group><article-title>The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin</article-title><source><italic>Journal of Physiology and Pharmacology</italic></source><year>2010</year><volume>61</volume><issue>6</issue><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="other">2-s2.0-79251519326</pub-id><pub-id pub-id-type="pmid">21224501</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonciarz</surname><given-names>M.</given-names></name><name><surname>Gonciarz</surname><given-names>Z.</given-names></name><name><surname>Bielanski</surname><given-names>W.</given-names></name><etal/></person-group><article-title>The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study</article-title><source><italic>Journal of Physiology and Pharmacology</italic></source><year>2012</year><volume>63</volume><issue>1</issue><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="other">2-s2.0-84859127888</pub-id><pub-id pub-id-type="pmid">22460459</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cichoz-Lach</surname><given-names>H.</given-names></name><name><surname>Celinski</surname><given-names>K.</given-names></name><name><surname>Konturek</surname><given-names>P. C.</given-names></name><name><surname>Konturek</surname><given-names>S. J.</given-names></name><name><surname>Slomka</surname><given-names>M.</given-names></name></person-group><article-title>The effects of l-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis</article-title><source><italic>Journal of Physiology and Pharmacology</italic></source><year>2010</year><volume>61</volume><issue>5</issue><fpage>577</fpage><lpage>580</lpage><pub-id pub-id-type="other">2-s2.0-78649657821</pub-id><pub-id pub-id-type="pmid">21081801</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardinali</surname><given-names>D. P.</given-names></name><name><surname>Hardeland</surname><given-names>R.</given-names></name></person-group><article-title>Inflammaging, metabolic syndrome and melatonin: a call for treatment studies</article-title><source><italic>Neuroendocrinology</italic></source><year>2016</year><volume>104</volume><issue>4</issue><fpage>382</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1159/000446543</pub-id><pub-id pub-id-type="pmid">27165273</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schemmer</surname><given-names>P.</given-names></name><name><surname>Nickkholgh</surname><given-names>A.</given-names></name><name><surname>Schneider</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PORTAL: pilot study on the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection: a double-blind randomized placebo-controlled trial</article-title><source><italic>BMC Surgery</italic></source><year>2008</year><volume>8, article 2</volume><pub-id pub-id-type="doi">10.1186/1471-2482-8-2</pub-id><pub-id pub-id-type="other">2-s2.0-39749114315</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickkholgh</surname><given-names>A.</given-names></name><name><surname>Schneider</surname><given-names>H.</given-names></name><name><surname>Sobirey</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The use of high-dose melatonin in liver resection is safe: first clinical experience</article-title><source><italic>Journal of Pineal Research</italic></source><year>2011</year><volume>50</volume><issue>4</issue><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1111/j.1600-079X.2011.00854.x</pub-id><pub-id pub-id-type="other">2-s2.0-79954419394</pub-id><pub-id pub-id-type="pmid">21480979</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>L. P. H.</given-names></name><name><surname>Werner</surname><given-names>M. U.</given-names></name><name><surname>Rosenkilde</surname><given-names>M. M.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of high-dose intravenous melatonin in humans</article-title><source><italic>The Journal of Clinical Pharmacology</italic></source><year>2016</year><volume>56</volume><issue>3</issue><fpage>324</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1002/jcph.592</pub-id><pub-id pub-id-type="other">2-s2.0-84958117538</pub-id><pub-id pub-id-type="pmid">26184078</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>L. P. H.</given-names></name><name><surname>Werner</surname><given-names>M. U.</given-names></name><name><surname>Rosenkilde</surname><given-names>M. M.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of oral and intravenous melatonin in healthy volunteers</article-title><source><italic>BMC Pharmacology and Toxicology</italic></source><year>2016</year><volume>17</volume><issue>1, article 8</issue><pub-id pub-id-type="doi">10.1186/s40360-016-0052-2</pub-id><pub-id pub-id-type="other">2-s2.0-84959190060</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooneratne</surname><given-names>N. S.</given-names></name><name><surname>Edwards</surname><given-names>A. Y. Z.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Cuellar</surname><given-names>N.</given-names></name><name><surname>Grandner</surname><given-names>M. A.</given-names></name><name><surname>Barrett</surname><given-names>J. S.</given-names></name></person-group><article-title>Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults</article-title><source><italic>Journal of Pineal Research</italic></source><year>2012</year><volume>52</volume><issue>4</issue><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="other">2-s2.0-84859733211</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-079X.2011.00958.x</pub-id><pub-id pub-id-type="pmid">22348451</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldhauser</surname><given-names>F.</given-names></name><name><surname>Waldhauser</surname><given-names>M.</given-names></name><name><surname>Lieberman</surname><given-names>H. R.</given-names></name><name><surname>Deng</surname><given-names>M.-H.</given-names></name><name><surname>Lynch</surname><given-names>H. J.</given-names></name><name><surname>Wurtman</surname><given-names>R. J.</given-names></name></person-group><article-title>Bioavailability of oral melatonin in humans</article-title><source><italic>Neuroendocrinology</italic></source><year>1984</year><volume>39</volume><issue>4</issue><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="other">2-s2.0-0021225301</pub-id><pub-id pub-id-type="doi">10.1159/000123997</pub-id><pub-id pub-id-type="pmid">6493445</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korkmaz</surname><given-names>A.</given-names></name><name><surname>Topal</surname><given-names>T.</given-names></name><name><surname>Tan</surname><given-names>D.-X.</given-names></name><name><surname>Reiter</surname><given-names>R. J.</given-names></name></person-group><article-title>Role of melatonin in metabolic regulation</article-title><source><italic>Reviews in Endocrine and Metabolic Disorders</italic></source><year>2009</year><volume>10</volume><issue>4</issue><fpage>261</fpage><lpage>270</lpage><pub-id pub-id-type="other">2-s2.0-77949264884</pub-id><pub-id pub-id-type="doi">10.1007/s11154-009-9117-5</pub-id><pub-id pub-id-type="pmid">19911281</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>R. J.</given-names></name><name><surname>Tan</surname><given-names>D.-X.</given-names></name><name><surname>Korkmaz</surname><given-names>A.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title>Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression</article-title><source><italic>Annals of Medicine</italic></source><year>2012</year><volume>44</volume><issue>6</issue><fpage>564</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.3109/07853890.2011.586365</pub-id><pub-id pub-id-type="other">2-s2.0-84865627272</pub-id><pub-id pub-id-type="pmid">21668294</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardinali</surname><given-names>D. P.</given-names></name><name><surname>Cano</surname><given-names>P.</given-names></name><name><surname>Jim&#x000e9;nez-Ortega</surname><given-names>V.</given-names></name><name><surname>Esquifino</surname><given-names>A. I.</given-names></name></person-group><article-title>Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications</article-title><source><italic>Neuroendocrinology</italic></source><year>2011</year><volume>93</volume><issue>3</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1159/000324699</pub-id><pub-id pub-id-type="other">2-s2.0-79953743149</pub-id><pub-id pub-id-type="pmid">21358175</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nduhirabandi</surname><given-names>F.</given-names></name><name><surname>du Toit</surname><given-names>E. F.</given-names></name><name><surname>Lochner</surname><given-names>A.</given-names></name></person-group><article-title>Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities?</article-title><source><italic>Acta Physiologica</italic></source><year>2012</year><volume>205</volume><issue>2</issue><fpage>209</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1111/j.1748-1716.2012.02410.x</pub-id><pub-id pub-id-type="other">2-s2.0-84860242302</pub-id><pub-id pub-id-type="pmid">22226301</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>V.</given-names></name><name><surname>Ohta</surname><given-names>Y.</given-names></name><name><surname>Espino</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Metabolic syndrome, its pathophysiology and the role of melatonin</article-title><source><italic>Recent Patents on Endocrine, Metabolic &#x00026; Immune Drug Discovery</italic></source><year>2013</year><volume>7</volume><issue>1</issue><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2174/187221413804660953</pub-id><pub-id pub-id-type="other">2-s2.0-84873106487</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walecka-Kapica</surname><given-names>E.</given-names></name><name><surname>Klupi&#x00144;ska</surname><given-names>G.</given-names></name><name><surname>Chojnacki</surname><given-names>J.</given-names></name><name><surname>Tomaszewska-Warda</surname><given-names>K.</given-names></name><name><surname>B&#x00142;o&#x00144;ska</surname><given-names>A.</given-names></name><name><surname>Chojnacki</surname><given-names>C.</given-names></name></person-group><article-title>The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women</article-title><source><italic>Przeglad Menopauzalny</italic></source><year>2014</year><volume>13</volume><issue>6</issue><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="other">2-s2.0-84924754308</pub-id><pub-id pub-id-type="doi">10.5114/pm.2014.47986</pub-id><pub-id pub-id-type="pmid">26327875</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname><given-names>S. S.</given-names></name><name><surname>Shulgin</surname><given-names>K. K.</given-names></name><name><surname>Popova</surname><given-names>T. N.</given-names></name><name><surname>Pashkov</surname><given-names>A. N.</given-names></name><name><surname>Agarkov</surname><given-names>A. A.</given-names></name><name><surname>de Carvalho</surname><given-names>M. A. A. P.</given-names></name></person-group><article-title>Effects of melatonin-aided therapy on the glutathione antioxidant system activity and liver protection</article-title><source><italic>Journal of Biochemical and Molecular Toxicology</italic></source><year>2015</year><volume>29</volume><issue>10</issue><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1002/jbt.21705</pub-id><pub-id pub-id-type="other">2-s2.0-84944157488</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozir&#x000f3;g</surname><given-names>M.</given-names></name><name><surname>Poliwczak</surname><given-names>A. R.</given-names></name><name><surname>Duchnowicz</surname><given-names>P.</given-names></name><name><surname>Koter-Michalak</surname><given-names>M.</given-names></name><name><surname>Sikora</surname><given-names>J.</given-names></name><name><surname>Broncel</surname><given-names>M.</given-names></name></person-group><article-title>Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome</article-title><source><italic>Journal of Pineal Research</italic></source><year>2011</year><volume>50</volume><issue>3</issue><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="other">2-s2.0-79952550270</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-079X.2010.00835.x</pub-id><pub-id pub-id-type="pmid">21138476</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>A.</given-names></name><name><surname>Terry</surname><given-names>P. D.</given-names></name><name><surname>Superak</surname><given-names>H. M.</given-names></name><etal/></person-group><article-title>Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial</article-title><source><italic>Diabetology and Metabolic Syndrome</italic></source><year>2014</year><volume>6</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="publisher-id">124</pub-id><pub-id pub-id-type="doi">10.1186/1758-5996-6-124</pub-id><pub-id pub-id-type="other">2-s2.0-84928645667</pub-id><pub-id pub-id-type="pmid">24383616</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Changes of aspartate aminotransferase (AST) levels during treatment of hyperlipidemia using statin with melatonin or with placebo.</p></caption><graphic xlink:href="BMRI2017-3204504.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes of alanine aminotransferase (ALT) levels during treatment of hyperlipidemia using statin with melatonin or with placebo.</p></caption><graphic xlink:href="BMRI2017-3204504.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Changes of gamma-glutamyltransferase (GGT) levels during treatment of hyperlipidemia using statin with melatonin or with placebo.</p></caption><graphic xlink:href="BMRI2017-3204504.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Changes of alkaline phosphatase (ALP) levels during treatment of hyperlipidemia using statin with melatonin or with placebo.</p></caption><graphic xlink:href="BMRI2017-3204504.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Comparison of the decrease (percentage %) of the aspartate aminotransferase (GGT), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), and alkaline phosphatase (ALP) levels before and after 6 months of treatment; all differences statistically significant, <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>p</italic> &#x0003c; 0,001.</p></caption><graphic xlink:href="BMRI2017-3204504.005"/></fig></floats-group></article>